With President Donald Trump and Democrats both seeking healthcare policy wins ahead of the 2020 presidential election, Congress will likely pass drug pricing legislation by the end of the year, according to an RBC Capital Markets investors note cited by CNBC.
"Dynamics into election look to be [a] perfect storm," RBC analyst Brian Abrahams wrote, according to CNBC. "While GOP leaders do not see drug-pricing reform as a top priority, both [House Speaker Nancy] Pelosi and [President] Trump are very committed to having policy change. "
Mr. Abrahams said that the drug-pricing reform package is likely to be a "middle-of-the-road" policy change.
Escalating drug costs in the U.S. have become a major issue, with both Democrats and Republican lawmakers working on bills to curb costs. A bipartisan bill from Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore., is making its way through the Senate.
Read the full report here.